CD274 and neoplasm: • Reducing the amount of suppressive immune factors • Immune factor antibodies (MDSC antibodies, tumor-associated macrophage antibodies, regulatory T cell antibodies) • CRISPR-Cas9 gene editing to knock out immune factor receptors• Fourth-generation CAR-T cells• Drug combination applications • PD-L1 inhibitors • Chemotherapy drugs• Targets that act on the tumor mesenchyme or microvasculature (FAP, CSPG4, etc.)• Optimizing the administration route of CAR-T cells (local injection)